Novopharm Ranitidine Advantage May Be "Insurmountable," Torpharm Argues
This article was originally published in The Tan Sheet
Apotex/Torpharm says the market advantage provided to competitor Novopharm by an award of 180-day market exclusivity for private label OTC ranitidine 75 mg may have long-term adverse effects on competing generic firms. The Apotex division filed a petition March 12 for a preliminary injunction against Novopharm in Chicago federal court.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC